Input Capital Corp. (CVE:INP) Ratings Coverage
Among 4 analysts covering Input Capital (CVE:INP), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Input Capital had 6 analyst reports since August 19, 2015 according to SRatingsIntel. The firm has “Sector Perform” rating by National Bank Canada given on Thursday, January 14. See Input Capital Corp. (CVE:INP) latest ratings:
Today, the insider of Vical Inc, Armistice Capital – Llc, invested in a huge amount company shares – 670,897, totalling $779,329 U.S Dollars, estimated based on $1.2 per each share. Because it was a sizable one trade, it’s not likely to stay unnoticed one. Armistice Capital – Llc presently owns 5.94 million shares or 27.24% of the Company’s market capitalization. A report obtainable for free here reveals this insider activity, that took place on June 13, 2018 and was filed with the (SEC).
Among 2 analysts covering Vical (NASDAQ:VICL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vical has $12 highest and $500 lowest target. $7’s average target is 554.21% above currents $1.07 stock price. Vical had 9 analyst reports since July 19, 2016 according to SRatingsIntel. The stock of Vical Incorporated (NASDAQ:VICL) earned “Buy” rating by H.C. Wainwright on Tuesday, July 19. H.C. Wainwright maintained Vical Incorporated (NASDAQ:VICL) rating on Wednesday, August 9. H.C. Wainwright has “Buy” rating and $900 target. The stock of Vical Incorporated (NASDAQ:VICL) earned “Buy” rating by H.C. Wainwright on Tuesday, November 21. H.C. Wainwright maintained Vical Incorporated (NASDAQ:VICL) rating on Friday, March 16. H.C. Wainwright has “Buy” rating and $5.0 target. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 12 report. The rating was reinitiated by Rodman \u0026 Renshaw on Monday, June 12 with “Buy”. The firm earned “Buy” rating on Monday, May 7 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, February 1 by H.C. Wainwright. The firm has “Buy” rating given on Monday, January 22 by H.C. Wainwright.
The stock decreased 5.31% or $0.06 during the last trading session, reaching $1.07. About 1.08 million shares traded or 469.15% up from the average. Vical Incorporated (NASDAQ:VICL) has declined 29.24% since June 14, 2017 and is downtrending. It has underperformed by 41.81% the S&P500. Some Historical VICL News: ; 15/03/2018 – VICAL INC – PROJECTING NET CASH BURN FOR 2018 BETWEEN $20 MLN AND $24 MLN; 03/05/2018 – Vical 1Q Loss $6.27M; 15/03/2018 – Vical 4Q Loss $3.73M; 15/03/2018 – Vical 4Q Rev $3.95M; 20/04/2018 – DJ Vical Incorporated, Inst Holders, 1Q 2018 (VICL); 03/05/2018 – VICAL INC – VICAL HAD CASH AND INVESTMENTS OF $58.3 MLN AT MARCH 31, 2018; 15/03/2018 Vical 4Q Loss/Shr 21c; 03/05/2018 – Vical 1Q Loss/Shr 29c
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company has market cap of $23.34 million. It is developing various DNA vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. It currently has negative earnings. The firm also engages in contract manufacturing of plasmid investigational products for various clients.
Analysts await Vical Incorporated (NASDAQ:VICL) to report earnings on August, 14. They expect $-0.27 earnings per share, up 10.00% or $0.03 from last year’s $-0.3 per share. After $-0.29 actual earnings per share reported by Vical Incorporated for the previous quarter, Wall Street now forecasts -6.90% EPS growth.
More important recent Vical Incorporated (NASDAQ:VICL) news were published by: Seekingalpha.com which released: “Vical: No Compelling Reason To Buy” on June 12, 2018, also Seekingalpha.com published article titled: “Vical’s HSV-2 vaccine flunks mid-stage study”, Streetinsider.com published: “Pre-Open Movers 06/11: (GNW) (RCII) (FDC) Higher; (VICL) (PCG) (AAOI) Lower (more..)” on June 11, 2018. More interesting news about Vical Incorporated (NASDAQ:VICL) was released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Dow Rises 80 Points; Nano Dimension Shares Spike Higher” with publication date: June 11, 2018.